Real-world evidence (RWE) has become an increasingly important source of data for regulatory decision-making in healthcare. The evolution of RWE regulations can be traced back to the late 1990s, when the US Food and Drug Administration (FDA) began to encourage the use of observational studies, such as registries and natural history studies, to supplement clinical trial data in the evaluation of medical products.

In 2011, the FDA launched the Sentinel Initiative, a program that uses electronic health records and other healthcare data sources to monitor the safety of medical products in real time. This initiative paved the way for the use of RWE in regulatory decision-making, and led to the development of guidelines and frameworks for the use of RWE in drug development and regulatory decision-making.

In 2016, the 21st Century Cures Act was signed into law in the US, which included provisions to support the use of RWE in regulatory decision-making. The Act directed the FDA to establish a program to evaluate the potential use of RWE to support drug approvals, and to issue guidance on the use of RWE in regulatory decision-making.

In 2018, the FDA issued its first guidance on the use of RWE to support drug approvals, which outlined the types of RWE that could be used, the study designs that could be employed, and the factors that would be considered in the evaluation of RWE. The guidance also emphasized the importance of ensuring the quality and reliability of RWE, and the need for transparent reporting and validation of RWE studies.

Since then, regulatory agencies around the world have continued to develop guidelines and frameworks for the use of RWE in regulatory decision-making. For example, the European Medicines Agency (EMA) has established a framework for the use of RWE in the evaluation of medicines, which includes the use of RWE to support marketing authorizations and post-authorization safety monitoring.

Overall, the evolution of RWE regulations reflects the growing recognition of the value of real-world data in healthcare decision-making, and the need for guidelines and frameworks to ensure the quality and reliability of RWE studies.